Protection of P53 Wild Type Cells from Taxol by Nutlin-3 in the Combined Lung Cancer Treatment

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2010 Feb 25

PMID 20178585

Citations 20

Authors

Sergey V Tokalov

Nasreddin D Abolmaali

Affiliations

Soon will be listed here.

Abstract

Background: Mutations within the tumor suppressor TP53 gene are one of the most common genetic alterations present at high frequency in human tumors and have been shown to be associated with resistance to radio-chemotherapy. The lack of the wild type TP53 gene in cancer cells could be exploited for therapeutic advantage using a sequence of two antagonistic drugs. The aim of this study was to selectively kill p53 deficient cells (FaDu and H1299) by taxol and to protect p53 wild type cells (A549) by the prior administration of nutlin-3 in comparison to certain known anticancer drugs (5-fluorouracil, camptothecin, roscovitine).

Methods: Cytotoxic and cytostatic properties of 5-fluorouracil, camptothecin, roscovitine and nutlin-3 administrating alone or in combination with taxol were investigated in vitro by flow cytometry.

Results: It was found that nutlin-3 induced growth arrest and protected A549 cells from taxol. FaDu and H1299 cells responded to the same treatments with mitotic arrest and massive apoptosis. Other compounds (5-fluorouracil, camptothecin and roscovitine) revealed weaker selectivity and elevated toxicity in comparison to nutlin-3.

Conclusions: We propose a therapeutic strategy protecting normal cells from taxol while increasing apoptosis selectively in p53-deficient cells using nutlin-3.

Citing Articles

Targeting Cell Cycle Facilitates E1A-Independent Adenoviral Replication.

Ehrenfeld M, Segeth F, Mantwill K, Brockhaus C, Zhao Y, Ploner C J Virol. 2023; 97(6):e0037023.

PMID: 37219458 PMC: 10308897. DOI: 10.1128/jvi.00370-23.

Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells.

Blagosklonny M Oncotarget. 2023; 14:193-206.

PMID: 36913303 PMC: 10010629. DOI: 10.18632/oncotarget.28382.

A Quantitative Systems Approach to Define Novel Effects of Tumour p53 Mutations on Binding Oncoprotein MDM2.

Fuentes M, Srivastava S, Gronenborn A, LaBaer J Int J Mol Sci. 2022; 23(1).

PMID: 35008477 PMC: 8744954. DOI: 10.3390/ijms23010053.

Investigating Core Signaling Pathways of Hepatitis B Virus Pathogenesis for Biomarkers Identification and Drug Discovery via Systems Biology and Deep Learning Method.

Chang S, Wang L, Chen B Biomedicines. 2020; 8(9).

PMID: 32878239 PMC: 7555687. DOI: 10.3390/biomedicines8090320.

Noninvasive assessment and quantification of tumor vascularization using [18F]FDG-PET/CT and CE-CT in a tumor model with modifiable angiogenesis-an animal experimental prospective cohort study.

Mirus M, Tokalov S, Abramyuk A, Heinold J, Prochnow V, Zophel K EJNMMI Res. 2019; 9(1):55.

PMID: 31227938 PMC: 6588673. DOI: 10.1186/s13550-019-0502-0.

References

Bhalla K . Microtubule-targeted anticancer agents and apoptosis. Oncogene. 2003; 22(56):9075-86. DOI: 10.1038/sj.onc.1207233. View

Tammemagi M, McLaughlin J, Bull S . Meta-analyses of p53 tumor suppressor gene alterations and clinicopathological features in resected lung cancers. Cancer Epidemiol Biomarkers Prev. 1999; 8(7):625-34. View

Zimmermann G, Lehar J, Keith C . Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007; 12(1-2):34-42. DOI: 10.1016/j.drudis.2006.11.008. View

Yu J, Zhang L . The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Commun. 2005; 331(3):851-8. DOI: 10.1016/j.bbrc.2005.03.189. View

Crescenzi E, Palumbo G, Brady H . Roscovitine modulates DNA repair and senescence: implications for combination chemotherapy. Clin Cancer Res. 2005; 11(22):8158-71. DOI: 10.1158/1078-0432.CCR-05-1042. View

Vassilev L . MDM2 inhibitors for cancer therapy. Trends Mol Med. 2006; 13(1):23-31. DOI: 10.1016/j.molmed.2006.11.002. View

Viktorsson K, De Petris L, Lewensohn R . The role of p53 in treatment responses of lung cancer. Biochem Biophys Res Commun. 2005; 331(3):868-80. DOI: 10.1016/j.bbrc.2005.03.192. View

Kranz D, Dobbelstein M . Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy. Cancer Res. 2006; 66(21):10274-80. DOI: 10.1158/0008-5472.CAN-06-1527. View

Sun S, Zheng M, Ding K, Wang S, Sun Y . A small molecule that disrupts Mdm2-p53 binding activates p53, induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Biol Ther. 2008; 7(6):845-52. DOI: 10.4161/cbt.7.6.5841. View

10.

Longley D, Harkin D, Johnston P . 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003; 3(5):330-8. DOI: 10.1038/nrc1074. View

11.

Tokalov S, Pieck S, Gutzeit H . Varying responses of human cells with discrepant p53 activity to ionizing radiation and heat shock exposure. Cell Prolif. 2007; 40(1):24-37. PMC: 6496140. DOI: 10.1111/j.1365-2184.2007.00421.x. View

12.

Blagosklonny M . Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs. Oncogene. 2002; 21(41):6249-54. DOI: 10.1038/sj.onc.1205793. View

13.

Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H . Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A. 2006; 103(6):1888-93. PMC: 1413632. DOI: 10.1073/pnas.0507493103. View

14.

Garcia-Carbonero R, Supko J . Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res. 2002; 8(3):641-61. View

15.

Folini M, Pennati M, Zaffaroni N . RNA interference-mediated validation of genes involved in telomere maintenance and evasion of apoptosis as cancer therapeutic targets. Methods Mol Biol. 2009; 487:303-30. DOI: 10.1007/978-1-60327-547-7_15. View

16.

Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C . Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J. 2001; 18(4):705-19. DOI: 10.1183/09031936.01.00062201. View

17.

Demidenko Z, Kalurupalle S, Hanko C, Lim C, Broude E, Blagosklonny M . Mechanism of G1-like arrest by low concentrations of paclitaxel: next cell cycle p53-dependent arrest with sub G1 DNA content mediated by prolonged mitosis. Oncogene. 2008; 27(32):4402-10. DOI: 10.1038/onc.2008.82. View

18.

Demidenko Z, Halicka D, Kunicki J, McCubrey J, Darzynkiewicz Z, Blagosklonny M . Selective killing of adriamycin-resistant (G2 checkpoint-deficient and MRP1-expressing) cancer cells by docetaxel. Cancer Res. 2005; 65(10):4401-7. DOI: 10.1158/0008-5472.CAN-04-4428. View

19.

Baumann M, Zips D, Appold S . Radiotherapy of lung cancer: technology meets biology meets multidisciplinarity. Radiother Oncol. 2009; 91(3):279-81. DOI: 10.1016/j.radonc.2009.05.001. View

20.

Vassilev L, Vu B, Graves B, Carvajal D, Podlaski F, Filipovic Z . In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004; 303(5659):844-8. DOI: 10.1126/science.1092472. View